Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: ...

Teva’s experimental anti-PD1-IL2 ATTENUKINE therapy is designed to selectively deliver interleukin-2 to PD-1-expressing T ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. UBS analyst ...

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of ...